We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bioelectronic Devices Capture and Release Tumor Cells for Early Cancer Diagnosis

By LabMedica International staff writers
Posted on 11 Sep 2023
Print article
Image: Microfabricated bioelectronic device for cell capture and release (Photo courtesy of UPV/EHU)
Image: Microfabricated bioelectronic device for cell capture and release (Photo courtesy of UPV/EHU)

Metastasis, the spread of cancer cells from the primary tumor to distant organs, is the main cause of cancer-related deaths. Metastasis occurs when a cancer cell detaches from the initial tumor, travels through the bloodstream and lymphatic system, and invades other parts of the body. Collecting these circulating tumor cells non-invasively is crucial for understanding cell biology, as well as for cancer diagnosis, prognosis, and drug development. Traditional methods for gathering these cells in a usable form are time-consuming, given that the concentration of these cells in the bloodstream is incredibly low compared to other cell types.

Now, a group of researchers at the University of the Basque Country (UPV/EHU, Leioa, Spain) has designed a bioelectronic device that could revolutionize this process. The device featuring gold electrodes coated with a smart polymer not only captures but also releases cells in a controllable, non-destructive manner, while simultaneously tracking these activities through standard electrical readings. This is seen as a foundational step toward creating universal systems for early cancer detection. Previous biosensors designed for this purpose were less than ideal because they damaged cells during the capture and release process. To address this, the team integrated smart materials with bioelectronics, which involves the use of carbon-based semiconductors, for more accurate and less harmful cell capture and release mechanisms.

In their preliminary tests, the researchers did not use real patient samples but instead relied on commercial cells sustained in culture media. The results demonstrated that the device successfully captured and released these cells. The team is now in the process of customizing the polymer to interact specifically with different types of cells. Currently, the device is being used on esophageal cancer patient samples. Its role is to selectively accumulate cancer cells, making it easier to determine their concentration in the sample.

“We wanted to come up with a device capable of concentrating cancer cells in order to detect their concentration,” said Janire Sáez, Ikerbasque research professor in the UPV/EHU’s Microfluidics Cluster Group. These are the first steps towards developing platforms for cancer screening. This could be a good step forward because they generally involve low-cost technologies and can be mass-produced. The idea is to use this type of technology for early cancer diagnosis.”

Related Links:
UPV/EHU 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.